Want to see DMAC full AI Analyst Report?
EarningsQ2 2026 Earnings Report
DMAC Q2 2026 EPS Results
Actual EPS-$0.19
Consensus EPS-$0.20
Beat/MissBeat by +$0.01
One Year Ago EPS-$0.18
DMAC Q2 2026 Revenue Results
Actual Revenue$0.00
Expected Revenue$0.00
Beat/MissMet expectations
YoY Revenue Growth―
Earnings Announcement Details
QuarterQ2 2026
Date08/10/2026
TimeAfter Close
Conference CallMonday, August 10, 2026
DMAC Upcoming Earnings
Diamedica Therapeutics's next earnings date is estimated for November 18, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DMAC Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted meaningful clinical progress: completion of the first FGR cohort, a supportive Part 1a preeclampsia data set with statistically significant blood pressure reductions and improved uterine perfusion signals, regulatory advances in Canada and planned expansions, and continued progress toward the ReMEDy2 interim analysis with broad site coverage. Financially, the company maintains a cash runway through 2027 but is experiencing a notable decline in cash and working capital versus year-end and materially higher R&D spend and operating cash burn. Operational and regulatory headwinds include enrollment variability, additional rat studies required for a U.S. IND, and a nonlinear dose-response that constrains higher-dose strategies. Overall, the positive clinical momentum and defined regulatory paths outweigh the financing and operational challenges in the near term.Company Guidance
Completed Enrollment in First Cohort of Phase II Fetal Growth Restriction (FGR) Study
Enrollment completed for cohort 1 (6 participants) at 5 µg/kg in open-label Phase II IST for early onset FGR, enabling expansion of DM199 into a second serious women's health indication with no approved therapies; cohort 2 (10 µg/kg) to begin shortly and cohort 3 dose to be chosen between 1–15 µg/kg based on emerging data.
Part 1a Extension Cohort Completed and Dose Selection Supported
Extension cohort (12 patients) plus initial dose escalation (3 patients) produced a 15-patient highest-dose analysis that guided selection of mid-dose range for future studies; mid-dose cohorts (4–8 µg/kg) produced the most clinically meaningful pharmacodynamic effects supporting further evaluation.
Statistically Significant Maternal Blood Pressure Reductions
In the highest-dose analysis (n=15) mean systolic blood pressure fell by 29.1 mmHg from a baseline of 169.3 mmHg (p < 0.001) and mean diastolic fell by 17.0 mmHg from 103.7 mmHg (p < 0.01); mean systolic remained below 160 mmHg at all measured time points over 24 hours.
Evidence of Improved Uterine/Placental Perfusion
Mid-dose cohorts showed clinically meaningful reductions in uterine artery pulsatility index (reduced placental vascular resistance), suggesting improved uterine-placental blood flow and a potential mechanism to modify disease in preeclampsia and FGR.
ReMEDy2 Enrollment Progressing Toward Interim Analysis
ReMEDy2 Phase II/III acute ischemic stroke study has surpassed 85% of the 200 patients required to trigger the prespecified interim efficacy analysis (i.e., ≈170+ patients); ~70 active sites across U.S., Canada, U.K. and 6 European countries; interim analysis anticipated in Q1 2027 after the 90-day follow-up window.
Regulatory and Operational Milestones Underway
Health Canada authorized initiation of an open-label Phase II dose-ranging early onset preeclampsia study (target ~30 patients across 3 dose levels); plan to dose first patient in Q4 2026 and expand to the U.K. pending authorization; preparing rat PK/pharmacologic study to address FDA questions for potential U.S. IND (study to complete early Sept with reports in Oct).
Strategic Dosing and Administration Plan
Company refined dosing strategy to target a mid-dose 'sweet spot' (approx. 4–8 µg/kg) and transition early onset programs to subcutaneous dosing every 3 days until delivery (with a continuous IV cohort in late-onset patients to explore finer BP control), informed by observed nonlinear dose-response and PD signals.
Cash Position and Runway Through 2027
As of June 30, 2026, cash, cash equivalents and short-term investments were $43.5M with working capital of $37.7M; management expects the cash position to fund planned clinical studies and operations through 2027, covering key upcoming milestones (ReMEDy2 interim, preeclampsia and FGR readouts).
DMAC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed